Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline Declines To License Theravance GI Motility Drug At Brink Of Phase III

This article was originally published in The Pink Sheet Daily

Executive Summary

Astellas deals Theravance a second blow by opting out on late-stage antibiotic candidate TD-1792, which could eventually compete with telavancin.

You may also be interested in...



The Good News for Biotech: New Regulation Opens A New Path to Profitability

REMS program may create new options for smaller companies targeting niche markets.

The Good News for Biotech: New Regulation Opens A New Path to Profitability

REMS program may create new options for smaller companies targeting niche markets.

Forest Teams Up With Microbia On IBS-C Agent Linaclotide

Firms plan to initiate Phase III studies in the second half of 2008.

Related Content

Topics

UsernamePublicRestriction

Register

PS066698

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel